Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study
Obesity · 2026
DOI: 10.1002/oby.70065 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Obesity, 2026. Verfasst von Zeyu Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Liraglutide, Recombinant Fusion Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Sanming Project of Medicine in Shenzen Municipality, the 2024 "Real-World Evidence and Health Technology Assessment for Clinical Use of Medicines" Special Project.
Abstract (Originalsprache)
Objective
We aimed to compare the effectiveness and safety of semaglutide 1.0 mg versus dulaglutide 1.5 mg and liraglutide 1.8 mg in patients with type 2 diabetes mellitus (T2DM) under routine clinical care.
Methods
This multicenter, retrospective, real‐world study enrolled Chinese adults with T2DM who initiated GLP‐1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024. We compared the effectiveness of these agents on HbA1c and weight loss, with safety as a key exploratory endpoint. Additionally, the UK Prospective Diabetes Study Outcomes Model 2.1 was utilized to project long‐term health outcomes.
Results
This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively. After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (−0.27% ± 0.70%, p = 0.008) and liraglutide (−0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates. Semaglutide was associated with improved outcomes in all death, cardiovascular death, and other death endpoints. No significant differences in safety profiles were observed among the three treatment groups.
Conclusions
Semaglutide demonstrated superior glycemic control and weight loss compared to both dulaglutide and liraglutide, whereas dulaglutide and liraglutide exhibited comparable clinical efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, China.
- Department of Pharmacy, Shenzhen Baoan People's Hospital, Shenzhen, Guangdong, China.
- Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
ORCID-Profile: Zeyu Xie
Förderung
- Sanming Project of Medicine in Shenzen Municipality
- the 2024 "Real-World Evidence and Health Technology Assessment for Clinical Use of Medicines" Special Project
Zitieren
APA
Xie, Z., Gan, B., Cao, W., Liu, J., & Chen, J. (2026). Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study. Obesity. https://doi.org/10.1002/oby.70065
Vancouver
Xie Z, Gan B, Cao W, Liu J, Chen J. Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study. Obesity. 2026. doi:10.1002/oby.70065
BibTeX
@article{Xie2026,
author = {Xie, Zeyu and Gan, Bin and Cao, Weiling and Liu, Jiang and Chen, Jisheng},
title = {Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70065}
}
EUVIMED